Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Nov 22, 2024

SELL
$6.75 - $13.52 $110,700 - $221,728
-16,400 Closed
0 $0
Q4 2021

Nov 22, 2024

BUY
$12.94 - $25.99 $212,216 - $426,236
16,400 New
16,400 $216 Million
Q4 2020

Nov 22, 2024

BUY
$23.94 - $46.81 $392,616 - $767,684
16,400 New
16,400 $607 Million

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $933M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.